Inovio Pharmaceuticals (INO) Expected to Announce Quarterly Earnings on Tuesday

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) is expected to release its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 13th. Analysts expect Inovio Pharmaceuticals to post earnings of ($0.74) per share and revenue of $0.01 million for the quarter.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.18. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.03 million. On average, analysts expect Inovio Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ INO traded down $0.01 during mid-day trading on Friday, reaching $1.82. The company had a trading volume of 427,875 shares, compared to its average volume of 589,321. The stock has a fifty day moving average of $1.80 and a two-hundred day moving average of $2.61. Inovio Pharmaceuticals has a 12-month low of $1.42 and a 12-month high of $13.44. The company has a market capitalization of $66.56 million, a price-to-earnings ratio of -0.45 and a beta of 1.40.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. StockNews.com lowered shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, May 2nd. Royal Bank of Canada lowered their target price on Inovio Pharmaceuticals from $6.00 to $5.00 and set a "sector perform" rating on the stock in a research note on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $3.00 price target on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $12.20.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.